Plain-English Summary

Semaglutide AUD Phase 2 studied semaglutide in Adults with alcohol use disorder in an early-phase human laboratory trial. Low-dose semaglutide reduced craving and some drinking outcomes.

Key Findings

• Low-dose semaglutide reduced craving and some drinking outcomes.
• Findings support larger randomized clinical trials of GLP-1 receptor agonists for alcohol use disorder.

Limitations

• Small early-phase trial.
• Short duration.
• Not sufficient to establish semaglutide as an approved AUD treatment.

Why It Matters

Alcohol self-administration and drinking-related outcomes

Viral Vitalism Verdict

Useful evidence, bounded by design: Small early-phase trial.

Sources

1. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder - JAMA Psychiatry / PubMed
2. Semaglutide for Alcohol Use Disorder - ClinicalTrials.gov